On Monday, OSE Immunotherapeutics reported "very promising" initial results from a Phase 1/2 clinical trial evaluating its monoclonal antibody in patients with solid tumors.

According to the biotech, these data showed initial signs of efficacy in the first 13 patients included, presenting eight tumor types, whether treated at doses of 100 and 300 mg every three weeks or 600 mg every six weeks.

In detail, three responses were reported in 11 patients with at least one post-inclusion tumor evaluation, including a partial response in a patient with hepatocellular carcinoma (81% tumor reduction) after a single 300 mg dose.

Two partial responses, not yet confirmed, were also observed at the 600 mg dose, one in a squamous cell anal carcinoma (46% tumor reduction) and the other in an undifferentiated pleomorphic sarcoma (33% tumor reduction).

In a press release, OSE reports "positive" initial results, which it considers "encouraging" for further clinical development of OSE-279 as a single agent in pre-identified niche indications involving cancers with high medical need.

"This product may also be explored in combination with other OSE drug candidates or with external assets, paving the way for potential new partnerships", explains the biotech company.

OSE-279 is a humanized anti-PD1 monoclonal antibody that blocks both PD1 ligands overexpressed by tumor cells and the tumor microenvironment, while targeting other novel immunotherapy targets.

The results of this trial were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which closed yesterday in Boston.

Listed on the Paris Bourse, OSE Immunotherapeutics shares climbed nearly 10% in early trading on Monday morning following this news.

Copyright (c) 2023 CercleFinance.com. All rights reserved.